Is Aptose Biosciences Inc. (APTO) a Buy, Sell, or Hold?
NASDAQ : APTO
Aptose Biosciences Inc.
$1.71 USD
$1.71 (0%)
- Volume
- 648.21K
- Average Volume
- 223.28K
- Market Capitalization
- $4.36M
- P/E Ratio
- -0.16
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $43.19
- Year Low
- $1.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.55
Company Overview
NASDAQ
William G. Rice
Biotechnology
Healthcare
APTO
35
CA
USD
Liquidity Metrics
0.00
0.55
0.55
0.09
0.00
Sales & Valuation
-$
0.00
-0.13
0.00
0.00
Profitability
-$10.41
-$
0.00%
0.00%
-23.18%
51.69%
P/E Metrics
-0.16
0.00
0.00
Analyst Price Target & Rating
0/5
11 Analysts
%
Financial Health Scores
-75.92
3/9
-$5.08M
$10.72M
$45.4M
-$1.47M
Key Metrics (TTM)
$3.42M
0.00
-2.33
0.55
-23.18%
-1252.52%
127.00%
0.00%
0 days
Company Executives
| Name | Title |
|---|---|
| William G. Rice | Chairman, President & Chief Executive Officer |
| Marc Wiles | Senior Vice President of Regulatory Affairs |
| Rafael Bejar | Senior Vice President & Chief Medical Officer |
| Fletcher Payne | Senior Vice President, Chief Financial Officer, Chief Business Officer & Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Aptose Biosciences Inc. (NASDAQ:APTO) Stock
Aptose Biosciences Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to discovering and advancing personalized therapeutic solutions to address critical unmet medical needs within the field of oncology, primarily focusing on the United States market. Its active clinical pipeline features several promising candidates. APTO-253 is currently undergoing Phase 1a/b clinical evaluation for patients battling relapsed or treatment-resistant blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another compound, HM43239, is progressing through Phase 1/2 clinical trials, specifically targeting individuals with relapsed or refractory AML. Furthermore, luxeptinib is in Phase 1a/b clinical testing, designed to treat patients suffe ... ring from recurring or treatment-resistant B-cell malignancies—such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas—as well as AML and HR MDS. Aptose also has APL-581 under development, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. The company has established strategic agreements with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986, Aptose Biosciences Inc. previously operated as Lorus Therapeutics Inc. before adopting its current name in August 2014. Its corporate headquarters are located in Toronto, Canada.
2026-06-15 07:30:00
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML 32 AML patients dosed across 40 mg, 80 mg, 120 mg and 160 mg TUS with TUS+VEN+AZA triplet Composite complete response (CRc) rate in evaluable patients across all dosing groups was 86.2% MRD-negativity in patients who achieved a CR/CRh response was 86.4% AML patients with diverse genetics, including TP53-mutated, complex karyotypes, and unmutated FLT3, safely achieved responses and MRD negativity SAN DIEGO and TORONTO, June 15, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, announced that data from its Phase 1/2 TUSCANY trial in newly diagnosed AML patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) was presented yesterday in an oral presentation at the European Hematology Association Congress (EHA 2026) in Stockholm, Sweden. The TUS+VEN+AZA triplet is being developed as a mutation agnostic frontline therapy to treat large, mutationally unrestricted and diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy.
Aptose Reports First Quarter 2026 Results
2026-05-13 17:00:00
SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. “Our TUSCANY clinical trial of tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML) continues to deliver robust safety and response data, and we're pleased that an update of our TUS+VEN+AZA triplet clinical data has been selected for an oral presentation at the upcoming EHA2026 Congress in June,” said William G.
Frequently Asked Questions
-
What is the current Aptose Biosciences Inc. (APTO) stock price?
-
Aptose Biosciences Inc.(NASDAQ:APTO) stock price is $1.71 in the last trading session. During the trading session, APTO stock reached the peak price of $43.191 while $1.1 was the lowest point it dropped to. The percentage change in APTO stock occurred in the recent session was 0% while the dollar amount for the price change in APTO stock was $1.71.
-
APTO's industry and sector of operation?
-
The NASDAQ listed APTO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of APTO?
-
William G. Rice | Chairman, President & Chief Executive Officer
Marc Wiles | Senior Vice President of Regulatory Affairs
Rafael Bejar | Senior Vice President & Chief Medical Officer
Fletcher Payne | Senior Vice President, Chief Financial Officer, Chief Business Officer & Secretary
| -
How many employees does APTO have?
-
Number of APTO employees currently stands at 35. APTO operates from 251 Consumers Road, Toronto, ON M2J 4R3, CA.
-
Link for APTO official website?
-
Official Website of APTO is: https://www.aptose.com
-
How do I contact APTO?
-
APTO could be contacted at phone #16507185028 and can also be accessed through its website. APTO operates from 251 Consumers Road, Toronto, ON M2J 4R3, CA.
-
How many shares of APTO are traded daily?
-
The average number of APTO shares traded daily for last 3 months was 223.28K.
-
What is the market cap of APTO currently?
-
The market value of APTO currently stands at $4.36M with its latest stock price at $1.71